Similar articles

• Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.

  Ionescu DF, Bentley KH, Eikermann M, Taylor N, Akeju O, Swee MB, Pavone KJ, Petrie SR, Dording C, Mischoulon D, Alpert JE, Brown EN, Baer L, Nock MK, Fava M, Cusin C. Ionescu DF, et al. J Affect Disord. 2019 Jan 15;243:516-524. doi: 10.1016/j.jad.2018.09.037. Epub 2018 Sep 17. J Affect Disord. 2019. PMID: 30286416 Clinical Trial.
• Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.

  Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, Ungvari GS, Correll CU, Chiu HF, Xue Y, Tian TF, Wu AS, Ma X, Wang G. Hu YD, et al. Psychol Med. 2016 Feb;46(3):623-35. doi: 10.1017/S0033291715002159. Epub 2015 Oct 19. Psychol Med. 2016. PMID: 26478208 Clinical Trial.
• Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

  Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV. Murrough JW, et al. Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298. Neuropsychopharmacology. 2015. PMID: 25374095 Free PMC article. Clinical Trial.
• Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine.

  Cui Y, Hu S, Hu H. Cui Y, et al. Trends Neurosci. 2019 Mar;42(3):179-191. doi: 10.1016/j.tins.2018.12.002. Trends Neurosci. 2019. PMID: 30823984 Review.
• A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.

  Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. Naughton M, et al. J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. J Affect Disord. 2014. PMID: 24388038 Review.